ICIs with PD-1, PD-L1, CTLA-4, TIM-3 and LAG-3 as representative targets have shown surprising safety and efficacy in the treatment of HCC (Table 1). The gene discussed is HAVCR2; the disease is hepatocellular carcinoma.